Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II (3MH-2)

Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase 2

The overall aim of this research is to develop a non-invasive approach to evaluate the production of 3-methylhistidine (3MH)in cancer patients, as a potential means of determining which patients are at high risk for future development of cancer induced skeletal muscle atrophy.

Rationale: The approach is based on the hypothesis that after an oral dose of deuterated 3-methylhistidine (D-3MH), the slope of the terminal portion of the decay curve (> 12 hours post-dosing) for the tracer/tracee (D-3MH/3MH) in the free 3MH pool is proportional to the rate constant for myofibrillar protein degradation and can be determined from spot urine samples.

Study Overview

• Status: Completed
• Conditions: Cachexia
• Intervention / Treatment: Biological: (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)

Detailed Description

The long-term objective of this research is to develop a non-invasive approach for assessment of de novo 3MH production in cancer patients early in the course of the disease as a way of assessing which patients are at high risk for future development of skeletal muscle atrophy. The approach is based on: 1) the known increase in de novo production of 3-methylhistidine (3MH) from muscle protein breakdown in said patients as a consequence of their unique disease-host interactions, and 2) earlier demonstration that de novo 3MH production can be measured in vivo using isotope dilution.

During this Phase-II project, we propose to conduct a statistically powerful prospective investigation to demonstrate that measurement of the slope of the terminal decay curve (rate constant) with our approach in newly diagnosed cancer patients predicts future development of muscle wasting. We expect the outcome of the combined Phase-I and Phase-II research to lead to the early identification of elevated muscle catabolism in at-risk patients so that medical intervention can prevent future muscle atrophy.

• Study Type: Observational
• Enrollment (Actual): 8

Contacts and Locations

Study Locations

• United States
  • Texas
    • Galveston, Texas, United States, 77555-0361
      • University of Texas Medical Branch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

We will conduct a longitudinal study (repeated measures design) in 30 newly diagnosed nonsmall cell lung cancer (NSCLC) patients who are not candidates for curative resection.

Description

Inclusion Criteria:

• (1) histological or cytological evidence of NSCLC without curative options;
• (2) over 18 years of age;
• (3) patient reported weight loss of ≤5% of usual body weight in the last 6 months;
• (4) life expectancy of greater than 6 months based on the judgement of treating physician;
• (5) serum creatinine ≤1.5 times the upper limit of normal; and
• (6) willing and able to give informed consent.

Exclusion Criteria:

• 1) malabsorption, intractable vomiting or gastrointestinal obstruction
• 2) congestive heart failure
• 3) edema or ascites
• 4) liver function test results that will preclude administration of prescribed therapy
• 5) pregnant, nursing, or, if of child-bearing age, unwilling to use contraceptives

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Newly Diagnosed NSCLC patients; In this study, newly diagnosed NSCLC patients who are not candidates for curative resection, will receive a (non-radioactive) oral dose of deuterated 3-methylhistidine (D-3MH).	Biological: (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH); Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Determination of myofibrillar protein degradation rate constant and slope of terminal decay curve.	Spot urine (multiple) collections between 12 to 17 hours of D-3MH ingestion.

Collaborators and Investigators

• Sponsor: The University of Texas Medical Branch, Galveston
• Investigators: Principal Investigator: William J Durham, PhD, The University of Texas Medical Branch (UTMB Health), Galveston, Texas.

Study record dates

Study Major Dates

• Study Start: November 1, 2012
• Primary Completion (Actual): June 1, 2015
• Study Completion (Actual): June 1, 2015

Study Registration Dates

• First Submitted: September 24, 2012
• First Submitted That Met QC Criteria: September 24, 2012
• First Posted (Estimate): September 27, 2012

Study Record Updates

• Last Update Posted (Estimate): July 2, 2015
• Last Update Submitted That Met QC Criteria: July 1, 2015
• Last Verified: July 1, 2015

More Information

Terms related to this study

• Keywords: Sarcopenia; Cachexia; De Novo; Deuterated
• Additional Relevant MeSH Terms: Metabolic Diseases; Nutrition Disorders; Body Weight; Body Weight Changes; Emaciation; Weight Loss; Wasting Syndrome; Cachexia
• Other Study ID Numbers: 12-064; 2R44AR054993-02 (U.S. NIH Grant/Contract)